Hans Jürgen Stellbrink

TL;DR: The T-20 vs. Optimized Regimen Only Study 2 (TORO 2) as discussed by the authors compared the efficacy and safety of 24 weeks of treatment with the fusion inhibitor enfuvirtide in combination with an optimized background antiretroviral regimen with the efficacy of the optimized background regimen alone.

TL;DR: Both long-acting regimens met primary criteria for comparability in viral suppression relative to the oral comparator group and the primary analysis used a Bayesian approach to evaluate the hypothesis that the proportion with viral suppression for each long- acting regimen is not worse than the oral regimen proportion.

TL;DR: Weight gain is ubiquitous in clinical trials of ART initiation and is multifactorial in nature, with demographic factors, HIV-related factors, and the composition of ART regimens as contributors.

TL;DR: Results are reported from a study comparing initial HIV-1 treatment with bictegravir with a novel INSTI with a high in-vitro barrier to resistance and low potential as a perpetrator or victim of clinically relevant drug interactions, showing non-inferiority of the bictricitabine regimen to the dolutegravIR regimen.

TL;DR: The study showed no difference in estimated glomerular filtration rate between the arms, however, increases in markers of tubular dysfunction were observed in the tenofovir/emtricitabine arm, the long-term consequence of which is unclear.